Global Cell Lysis Market Opportunities, 2031

Cell lysis is the process of breaking open cell membranes and, where present, cell walls to release DNA, RNA, proteins, organelles, metabolites or viral vectors for analysis, purification or manufacturing. It is a first step in a wide range of workflows, including nucleic acid extraction for sequencing and diagnostics, protein expression and purification, proteomics, single-cell analysis, recombinant protein and plasmid manufacturing and the harvest of viral vectors for gene therapy. Methods fall into two broad groups: mechanical techniques such as bead beating, high-pressure homogenisation, sonication and freeze-thaw cycles, and non-mechanical techniques such as detergent-based reagents, chaotropic salts, enzymes like lysozyme and proteinase K, osmotic shock and alkaline lysis. The best method depends on the sample, from fragile mammalian cells to tough bacteria, yeast, plant tissue, spores and soil. Bead beating instruments can lyse tough samples in seconds to minutes, while detergent reagents gently release proteins in their active form. Leading suppliers include Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher, Promega, Roche, Takara Bio, New England Biolabs, Agilent, Covaris, Bertin Technologies, MP Biomedicals, Avestin and Microfluidics. Yield, reproducibility and compatibility with downstream steps determine competitiveness.

Demand is driven by the growth of genomics, proteomics and single-cell analysis, molecular diagnostics, biologics and cell and gene therapy manufacturing, and the need for automated, reproducible sample preparation. Between 2024 and 2026, the industry consolidated around sample preparation and purification: a major tools company completed the acquisition of a high-throughput proteomics firm in July 2024, the same company agreed in February 2025 and completed in September 2025 a roughly 4 billion dollar acquisition of a purification and filtration business used in bioprocessing, and a sample technologies company agreed in November 2025 to acquire a single-cell analysis provider. Regulators approved new gene therapies, including a viral vector therapy delivered directly to the brain in November 2024, sustaining demand for scalable lysis and clarification in vector manufacturing. Suppliers launched new fixation and sample preparation products for single-cell studies. Challenges included variability between sample types, interference of lysis reagents with downstream assays, scale-up in manufacturing and pressure on research budgets. Through 2031, key variables are sequencing and proteomics growth, automation, gene therapy manufacturing scale, diagnostics volumes and research funding. Suppliers with integrated, automated and scalable solutions are expected to hold an advantage.

Drivers •Growth of Genomics, Proteomics and Single-Cell Analysis: Sequencing, proteomics, spatial biology and single-cell studies all begin with efficient and reproducible lysis that preserves the molecules of interest. Falling sequencing costs and large population genomics, cancer and microbiome studies increase sample volumes. High-throughput proteomics platforms and single-cell methods need specialised lysis and fixation reagents. Automation of sample preparation is spreading to handle volumes. Demand is strong.

•Biologics and Cell and Gene Therapy Manufacturing: Production of recombinant proteins, plasmid DNA, mRNA templates and viral vectors such as adeno-associated virus and lentivirus requires scalable lysis steps to release products from host cells, followed by clarification and purification. Growth in gene therapy approvals and clinical programmes increases demand for large-scale lysis reagents, homogenisers and process-compatible detergents. Manufacturers seek methods that meet regulatory and environmental requirements. Growth is solid.

Challenges •Sample Variability and Downstream Compatibility: Different cell types and tissues require different lysis conditions, and methods that work for mammalian cells may fail for bacteria, yeast, spores or plant material. Harsh methods can damage proteins or shear DNA, while gentle methods may leave cells intact. Detergents, salts and enzymes can interfere with downstream assays such as mass spectrometry or PCR. Optimisation takes time. Reproducibility is a concern. Protocols vary widely.



•Scale-Up, Regulatory and Cost Pressures: Moving lysis from laboratory to manufacturing scale can change efficiency and product quality, and processes must be validated for consistency. Some traditional detergents face environmental restrictions, requiring replacement with alternatives that must be re-validated. Research funding pressure in some markets limits spending on instruments. Price competition is strong for reagents. Supply chain resilience matters. Margins are tight.

Trends •Automated, High-Throughput and Integrated Sample Preparation: Laboratories are adopting automated systems that combine lysis, extraction and purification in one workflow, using liquid handling robots, magnetic bead platforms and integrated cartridges, reducing hands-on time and variability. Diagnostic systems use closed cartridges that include lysis steps. Single-cell and spatial platforms offer integrated fixation and lysis kits. Companies are consolidating sample preparation portfolios. Adoption is rising.

•Gentle, Sustainable and Process-Compatible Lysis Reagents: Suppliers are developing detergent alternatives that meet environmental rules, animal-origin-free and good manufacturing practice-grade reagents for therapy production, and gentle lysis buffers optimised for viral vector release with high infectivity. Mechanical methods with better temperature control protect sensitive molecules. Reagents compatible with mass spectrometry and sequencing reduce clean-up steps. Product ranges are expanding. Interest is growing.

Reagents and consumables lead because every lysis workflow consumes buffers, enzymes, kits and tubes, while instruments grow with automation and bioprocessing investment. Reagents and consumables are the largest product segment because every lysis procedure uses buffers, detergents, enzymes, chaotropic reagents, kits, bead tubes and other consumables, creating recurring demand that rises with sample volumes in research, diagnostics and manufacturing. Ready-to-use kits for specific sample types, such as blood, tissue, bacteria, plants and cultured cells, simplify workflows and reduce variability. Good manufacturing practice-grade reagents for biologic and viral vector production command higher prices. Instruments, including bead beating homogenisers, high-pressure homogenisers, sonicators, microfluidic devices and automated extraction systems, form a large segment that grows with laboratory automation, high-throughput genomics and bioprocessing investment. Instruments are often bought with long-term consumables contracts. Accessories and services, including installation, maintenance, validation and method development, support these systems. Integrated platforms that combine lysis with extraction and purification are becoming common in molecular diagnostics and sequencing laboratories. Process-scale homogenisers and lysis systems are used in manufacturing facilities producing proteins, plasmids and viral vectors. Most categories serve research laboratories and regulated manufacturing customers. Through the forecast period, reagents and consumables are expected to remain the largest segment, while instruments grow steadily with automation and bioprocessing capacity, and services grow as manufacturers require validated processes for regulated therapeutic production at commercial scale.


Reagent-based lysis leads because detergents and enzymes are simple and scalable, while mechanical methods grow for tough samples and high-throughput workflows. Reagent-based lysis, using detergents, enzymes, chaotropic salts, alkaline solutions or osmotic shock, is the largest technique segment because it is simple, requires little equipment, scales well from microplates to manufacturing vessels and can be tuned to release specific molecules gently. It is widely used for mammalian cell culture, protein extraction, plasmid preparation and viral vector release. Enzymatic methods using lysozyme, proteinase K, lyticase or other enzymes are important for bacteria, yeast and tissue samples. Mechanical lysis, including bead beating, high-pressure homogenisation, sonication, grinding and freeze-thaw, is the fastest growing segment because it handles tough samples such as bacteria, fungi, spores, plant tissue, soil and stool, and it supports microbiome, environmental and food testing as well as large-scale manufacturing. Mechanical methods avoid chemicals that may inhibit downstream reactions. Combined approaches, such as enzymatic pre-treatment followed by bead beating, are common for difficult samples. Microfluidic and electrical lysis methods are emerging for single-cell and point-of-care applications. Choosing the technique depends on sample toughness, target molecule, throughput and downstream analysis requirements. Through the forecast period, reagent-based lysis is expected to remain the largest segment, while mechanical and combined methods grow fastest as microbiome research, sequencing volumes and bioprocessing scale continue to expand worldwide.


Mammalian cells lead because most biomedical research and biologic manufacturing use them, while microbial cells grow with microbiome, diagnostics and plasmid production. Mammalian cells are the largest cell type segment because much biomedical research, drug discovery, cell-based assays, proteomics, single-cell analysis and the manufacture of antibodies and viral vectors rely on human and animal cells, which are relatively easy to lyse but require gentle methods to preserve protein function and vector infectivity. Blood and tissue samples used in clinical research and diagnostics also fall into this category. Bacterial cells are a major segment because they are used to produce recombinant proteins, plasmid DNA and enzymes, and because infectious disease diagnostics, antimicrobial resistance testing and microbiome studies require efficient lysis of diverse bacteria, including tough gram-positive species. Yeast and fungal cells require stronger mechanical or enzymatic methods because of their rigid cell walls, and they are important in research, food and industrial biotechnology. Plant cells and algae require specialised methods for agricultural genomics and biotechnology. Insect cells are used in some protein and vector manufacturing systems. Each cell type therefore needs specific reagents, instruments and carefully validated protocols. Through the forecast period, mammalian cells are expected to remain the largest segment, while microbial cells grow fastest with microbiome research, diagnostics, plasmid manufacturing and industrial biotechnology applications that require robust lysis of difficult organisms.


Pharmaceutical and biotechnology companies lead because research and manufacturing consume large volumes, while diagnostic laboratories and contract organisations grow fastest. Pharmaceutical and biotechnology companies are the largest end-user group because they use cell lysis extensively in drug discovery, target validation, proteomics, biologic development and manufacturing of proteins, plasmids and viral vectors, and they buy both laboratory kits and process-scale systems. Gene therapy developers in particular require scalable and validated lysis steps for vector harvest. Academic and research institutes are a large user group, carrying out genomics, proteomics, cell biology, microbiology and single-cell research that begins with lysis, although spending depends on research funding. Hospitals and diagnostic laboratories are a fast-growing group because molecular diagnostics, infectious disease testing, oncology testing and sequencing-based tests require reliable and often automated lysis and extraction. Contract research and manufacturing organisations are growing quickly as drug developers outsource discovery, testing and production. Food, environmental and agricultural testing laboratories use lysis for pathogen detection, microbiome analysis and genetically modified organism testing. Forensic laboratories rely on lysis to recover DNA from difficult samples. Purchasing decisions balance yield, speed and cost per sample. Through the forecast period, diagnostic laboratories and contract organisations are expected to grow fastest, while pharmaceutical and biotechnology companies remain the largest users as biologic and gene therapy pipelines expand and manufacturing moves to larger scale.



North America is the leading region, supported by large life science research budgets, major biopharmaceutical and gene therapy companies, contract manufacturers and leading tools suppliers. Thermo Fisher Scientific completed its acquisition of Olink in July 2024 and completed the roughly 4 billion dollar acquisition of Solventum's purification and filtration business in September 2025, strengthening sample preparation and bioprocessing portfolios. The approval of Kebilidi, an adeno-associated virus gene therapy, in November 2024 reflected continued gene therapy progress. Research funding uncertainty affected academic spending. By 2031, growth is expected from genomics, proteomics, diagnostics and gene therapy manufacturing.

Europe is a major region with strong academic research, biopharmaceutical companies and bioprocessing suppliers such as Merck KGaA, QIAGEN and Sartorius. QIAGEN agreed in November 2025 to acquire Parse Biosciences for about 225 million dollars upfront, expanding its sample technologies into single-cell analysis. Environmental rules on certain detergents have encouraged reformulation of lysis reagents. Large biobank and genomics projects increase sample volumes. By 2031, growth is expected from single-cell and proteomics research, diagnostics and biologic manufacturing.

Asia-Pacific is the fastest growing region. China has a fast-growing biotechnology sector, large contract research and manufacturing organisations and major genomics companies, and domestic suppliers compete on price. Japan and South Korea have strong research and biomanufacturing industries. India's biosimilar, vaccine and contract research sectors are expanding. Singapore and Australia invest in life science research. By 2031, the region is expected to show the highest growth.

Latin America is a growing region where cell lysis is used in academic research, molecular diagnostics, agriculture and food testing in Brazil, Mexico and Argentina, along with vaccine production. Barriers include funding and import costs. By 2031, growth is expected from diagnostics and biotechnology.

The Middle East and Africa are developing regions. Gulf countries are investing in genomics programmes and biotechnology research, and Israel has a strong life science sector. African laboratories use lysis for infectious disease diagnostics and research, often supported by international funding. By 2031, growth is expected from Gulf genomics and diagnostics.

December 2025: Parse Biosciences launches Evercode Whole Blood Fixation: The product extends sample fixation for single-cell analysis to whole blood, supporting preparation of samples before cell lysis and barcoding.

November 2025: QIAGEN agrees to acquire Parse Biosciences: QIAGEN agreed to buy the single-cell company for about 225 million dollars upfront, expanding its sample technologies portfolio into scalable single-cell solutions.

September 2025: Thermo Fisher completes acquisition of Solventum's purification and filtration business: The roughly 4 billion dollar deal, agreed in February 2025, added purification and filtration technologies used in bioprocessing and downstream processing.

November 2024: FDA approves Kebilidi gene therapy: The adeno-associated virus gene therapy for AADC deficiency was approved, reflecting growth in viral vector therapies whose manufacturing depends on scalable cell lysis and clarification.

July 2024: Thermo Fisher completes acquisition of Olink: The acquisition added high-throughput proteomics technology, increasing focus on sample preparation for large-scale protein analysis.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Cell Lysis Market with its segments and regional outlook
• Various drivers and challenges
• Ongoing trends and developments
• Key developments and regulatory milestones

By Product
• Reagents and consumables
• Instruments
• Accessories and services

By Technique
• Reagent-based lysis
• Enzymatic lysis
• Mechanical lysis
• Microfluidic and other methods

By Cell Type
• Mammalian cells
• Bacterial cells
• Yeast and fungal cells
• Plant cells and algae
• Insect cells

By End User
• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Hospitals and diagnostic laboratories
• Contract research and manufacturing organisations
• Food, environmental and agricultural testing